Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment
Nicholas Denton(Nationwide Children's Hospital), Timothy P. Cripe(Nationwide Children's Hospital), Thomas R. Scott(Nationwide Children's Hospital), William F. Goins(University of Pittsburgh), Rachelle Srinivas(Nationwide Children's Hospital), Mark A. Currier(Nationwide Children's Hospital), Kevin A. Cassady(Nationwide Children's Hospital), Jennifer L. Leddon(University of Cincinnati), Pin-Yi Wang(Nationwide Children's Hospital), Brooke Nartker(Nationwide Children's Hospital), Chun‐Yu Chen(Guangdong Pharmaceutical University), Brian Hutzen(Nationwide Children's Hospital)
Cited by 56
Related Papers
Mre11 Nuclease Activity Has Essential Roles in DNA Repair and Genomic Stability Distinct from ATM Activation
|Cell|2008|341
Covalently Linked Au Nanoparticles to a Viral Vector: Potential for Combined Photothermal and Gene Cancer Therapy
|Nano Letters|2006|260
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
|Clinical Cancer Research|2017|137
Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
|Molecular Cancer Therapeutics|2008|128